Lupin Q1 FY27: Revenue ₹8,277 Cr, EBITDA ₹2,463 Cr

Record quarter sets a new operating benchmark

Lupin Ltd (NSE: LUPIN) used its Q1 FY27 earnings call on August 7, 2026 to highlight what management called a record quarter for the company. The drugmaker said total revenues from operations and EBITDA crossed ₹8,000 crore and ₹2,400 crore, respectively, for the first time in its history. The company also described the quarter as its 16th consecutive quarter of year-on-year growth.

For the quarter ended June 30, 2026, Lupin reported revenue from operations of ₹8,276.89 crore versus ₹6,268.34 crore a year earlier. Consolidated profit after tax (PAT) rose 16% year-on-year to ₹1,416.98 crore, supported by strong growth across key markets. While the quarter was positioned as a milestone, some market coverage noted earnings per share (EPS) of 28.7 versus a 29.24 forecast, indicating the headline beat on revenue did not translate into a clear EPS beat across all estimates.

Key financials: revenue up 32%, EBITDA up about 50%

On the call, management said revenue from operations grew 32% year-on-year to ₹8,277 crore. Lupin also reported EBITDA excluding forex and other income of ₹2,464 crore, up 50% year-on-year, reflecting stronger operating performance. A separate financial summary put Q1 FY27 EBITDA (excluding other income) at ₹2,463 crore versus ₹1,641 crore in Q1 FY26, with EBITDA margin at 29.76% compared with 26.19% a year earlier.

Net profit growth was more moderate than operating profit growth. PAT for Q1 FY27 was reported at ₹1,417 crore in one summary, compared with ₹1,221 crore in Q1 FY26. The same summary showed PAT margin at 17.12% versus 19.49% in the year-ago quarter, indicating margin pressure at the profit line despite the EBITDA expansion.

Expenses rise alongside scale-up in operations

Lupin disclosed that total expenses in the quarter rose to ₹6,389.83 crore from ₹4,931.84 crore in the corresponding period last year. This increase in expenses sits alongside commentary in market coverage that net income margin declined to 17.2% from 19.8% year-on-year, reflecting higher operating expenses and competitive pressures.

The gap between EBITDA growth and PAT margin movement is important for investors tracking operating leverage. The company still delivered a step-up in EBITDA margin to near 30% in Q1 FY27, but the broader cost base increase meant PAT margin moved lower versus the year-ago quarter. Lupin also noted that the quarter’s profit was marginally lower compared with the previous quarter, as indicated by the QoQ PAT change in the financial summary.

India business: 13.9% growth, diabetes strength stands out

Management highlighted that the India business grew 13.9% year-on-year in the quarter. Within India, the core prescription business grew 15.1% and was described as representing 1.1x growth against the Indian Pharmaceutical Market (IPM). The company linked part of the performance to strong execution in chronic therapies, and it cited diabetes as a standout segment with 31.8% growth.

Lupin also stated an ambition to increase the chronic segment share to 70%. While the earnings call did not quantify a timeline in the provided details, the target signals continued emphasis on chronic therapies, where prescription stickiness and brand strength can support steadier growth.

Regional mix: domestic sales and other developed markets

Market coverage of the quarter reported domestic sales in India increased 14% year-on-year to ₹2,379.6 crore. The same coverage said other developed markets grew 48.3% to ₹1,149.4 crore. Another investor results note said India formulations grew 13.9% to ₹2,379.6 crore and represented 29% of total sales.

These region-level numbers help explain how Lupin achieved a quarter where consolidated revenue crossed ₹8,000 crore. They also offer a snapshot of where growth was strongest, with sharp expansion in other developed markets alongside steady double-digit growth in India.

Snapshot table: Q1 FY27 versus Q1 FY26

Market impact: milestone quarter, but estimates still matter

From a market-read perspective, the quarter combined a clear scale milestone with a mixed signal on consensus comparisons. Reported revenue crossed ₹8,000 crore, and another coverage note said revenue of ₹8,277 crore topped an estimate of ₹7,854 crore. But EPS, as cited in the same coverage, was marginally below a forecast (28.7 versus 29.24), which can temper near-term sentiment even when operational performance is strong.

For investors, the operating trend was defined by EBITDA expansion to roughly 30% margin and the first quarter with EBITDA above ₹2,400 crore. At the same time, disclosed expenses rose to ₹6,389.83 crore, and PAT margin was lower than the year-ago quarter in the financial summary. This combination keeps attention on how sustainable the margin profile is as the company grows.

Analysis: what stands out from the call highlights

Two elements stand out in the disclosed details. First, Lupin’s management framed the quarter as structurally stronger, pointing to 16 consecutive quarters of year-on-year growth and record revenue and EBITDA levels. Second, the India franchise remained a key contributor, with 13.9% growth and a sharper 15.1% increase in core prescription, supported by diabetes growth of 31.8%.

The quarter also shows the difference between operating momentum and bottom-line margin outcomes. EBITDA grew roughly 50% year-on-year, but PAT margin was reported lower year-on-year, reflecting higher costs. For analysts, that makes the trajectory of expenses and competitive dynamics a central watch-point, alongside the company’s stated intent to push chronic share toward 70%.

What investors can track next

Lupin said it has made the audio recording of its Q1 FY27 earnings call available, following the announcement of results for the quarter ended June 30, 2026. Investors tracking the story will likely focus on management commentary around the drivers of top-line growth, the durability of near-30% EBITDA margins, and how expense growth trends over the next quarters.

The quarter sets a new benchmark for scale, with revenue from operations at ₹8,277 crore and EBITDA at about ₹2,463 crore. The next set of updates from the company, including subsequent quarterly results and follow-through on the India chronic share objective, will shape how the market assesses the sustainability of this record performance.